Amended Statement of Beneficial Ownership (sc 13d/a)
May 22 2015 - 4:47PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(Rule 13d-101)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Achillion Pharmaceuticals, Inc.
|
|
(Name of Issuer)
|
|
Common Stock, $.001 par value
|
|
(Title of Class of Securities)
|
|
00448Q201
|
|
(CUSIP Number)
|
| |
Domain Associates, LLC
|
Ropes & Gray LLP
|
| |
One Palmer Square
|
1211 Avenue of the Americas
|
| |
Princeton, NJ 08542
|
New York, NY 10036
|
| |
Attn: Kathleen K. Schoemaker
|
Attn: Morri Weinberg, Esq.
|
| |
Tel: (609) 683-5656
|
Tel: (212) 596-9000
|
|
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
|
| |
|
May 21, 2015
|
|
(Date of Event Which Requires Filing of This Statement)
|
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [ ]
Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 00448Q201
|
1.
|
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (VOLUNTARY)
Domain Partners VIII, L.P.
|
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) [X]
(b) [ ]
|
| |
SEC USE ONLY
|
|
|
4.
|
SOURCE OF FUNDS
|
Not applicable
|
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
|
[ ]
|
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
Delaware
|
|
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
|
5,663,507*
|
|
8.
|
SHARED VOTING POWER
|
0
|
|
9.
|
SOLE DISPOSITIVE POWER
|
5,663,507*
|
|
10.
|
SHARED DISPOSITIVE POWER
|
0
|
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
5,663,507*
|
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
[ ] |
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
4.7%
|
|
14.
|
TYPE OF REPORTING PERSON
|
PN
|
*Includes 2,790,539 shares issuable upon exercise of Warrants.
CUSIP No. 00448Q201
|
1.
|
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (VOLUNTARY)
DP VIII Associates, L.P.
|
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) [X]
(b) [ ]
|
| |
SEC USE ONLY
|
|
|
4.
|
SOURCE OF FUNDS
|
Not applicable
|
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
|
[ ]
|
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
Delaware
|
|
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
|
79,867*
|
|
8.
|
SHARED VOTING POWER
|
0
|
|
9.
|
SOLE DISPOSITIVE POWER
|
79,867*
|
|
10.
|
SHARED DISPOSITIVE POWER
|
0
|
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
79,867*
|
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
[ ] |
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
Less than 0.1%
|
|
14.
|
TYPE OF REPORTING PERSON
|
PN
|
*Includes 20,706 shares issuable upon exercise of Warrants.
CUSIP No. 00448Q201
|
1.
|
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (VOLUNTARY)
Domain Associates, LLC
|
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a) [X]
(b) [ ]
|
| |
SEC USE ONLY
|
|
|
4.
|
SOURCE OF FUNDS
|
Not applicable
|
|
5.
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
|
[ ]
|
|
6.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
Delaware
|
|
NUMBER OF SHARES
BENEFICIALLY OWNED
BY EACH REPORTING
PERSON WITH
|
7.
|
SOLE VOTING POWER
|
25,000
|
|
8.
|
SHARED VOTING POWER
|
0
|
|
9.
|
SOLE DISPOSITIVE POWER
|
25,000
|
|
10.
|
SHARED DISPOSITIVE POWER
|
0
|
|
11.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
25,000
|
|
12.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
|
13.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
Less than 0.1%
|
|
14.
|
TYPE OF REPORTING PERSON
|
OO
|
CUSIP No. 00448Q201
AMENDMENT NO. 4 TO SCHEDULE 13D
Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission (the “Commission”) by the Reporting Persons with respect to the Common Stock of the Issuer on August 30, 2010, Amendment No. 1 thereto filed on June 15, 2012, Amendment No. 2 thereto filed on January 18, 2013 and Amendment No. 3 thereto filed on September 11, 2014 (as so amended, the “Schedule 13D”). Terms used in the Schedule 13D are used herein as so defined.
The following items of the Schedule 13D are hereby amended as follows:
|
Item 5.
|
Interest in Securities of the Issuer.
|
| |
|
|
Item 5(a) is hereby amended and restated to read in its entirety as follows:
|
|
|
|
| |
(a)
|
The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment No. 4 to Schedule 13D. This information is based on a total of 117,558,885 shares of Common Stock outstanding as of May 1, 2015, as reported in the Issuer’s Report on Form 10-Q for the period ended March 31, 2015 filed with the Commission on May 7, 2015, and gives effect to the exercise of all Warrants held by the Reporting Persons. In addition to the shares that OPSA VIII indirectly beneficially owns in its capacity as the general partner of DP VIII and DP VIIIA, OPSA VIII directly beneficially owns 483,521 shares of Common Stock, or approximately 0.4% of the Common Stock outstanding.
|
| |
|
|
|
Item 5(c) is hereby amended and restated to read in its entirety as follows:
|
| |
|
|
| |
(c)
|
On May 21, 2015, DP VIII distributed in kind 1,700,000 shares of Common Stock pro rata to its partners, including 222,630 shares to OPSA VIII.
|
CUSIP No. 00448Q201
SIGNATURES
After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Dated: May 22, 2015
| |
DOMAIN PARTNERS VIII, L.P.
|
| |
By:
|
One Palmer Square Associates VIII, LLC, General Partner
|
| |
By:
|
/s/ Kathleen K. Schoemaker
|
| |
|
Managing Member
|
| |
DP VIII ASSOCIATES, L.P.
|
| |
By:
|
One Palmer Square Associates VIII, LLC., General Partner
|
| |
By:
|
/s/ Kathleen K. Schoemaker
|
| |
|
Managing Member
|
| |
DOMAIN ASSOCIATES, LLC
|
| |
|
|
| |
By:
|
/s/ Kathleen K. Schoemaker
|
| |
|
Managing Member
|
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024
